Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Brief Summary: The purpose of this study is to demonstrate the non-inferiority of the concomitant administration of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) and seasonal influenza vaccine versus the administration of seasonal influenza vaccine alone in terms of humoral immune response expressed by the geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody titers against all four influenza vaccine strains 28 days after the administration of influenza vaccine, and to assess the safety and tolerability of a single dose of 1\*10\^11 viral particles (vp) of Ad26.RSV.preF, administered intramuscularly to participants aged greater than or equal to 60 years separately or concomitantly with seasonal influenza vaccine.


Options:
A: Arm Label: 1 and 2 - Adults; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3A - Seropositive Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 3B - Seropositive Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 4A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 4B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 5A - Seronegative Infants and Children; Type: EXPERIMENTAL; Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine | Arm Label: 5B - Seronegative Infants and Children; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine; Assigned to Arm(s): 1 and 2 - Adults, 3A - Seropositive Children, 4A - Seronegative Infants and Children, 5A - Seronegative Infants and Children | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3B - Seropositive Children, 4B - Seronegative Infants and Children, 5B - Seronegative Infants and Children
B: Arm Label: Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Ad26.RSV.preF, Biological: Fluarix, Biological: Placebo | Arm Label: Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Ad26.RSV.preF, Biological: Fluarix, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Ad26.RSV.preF; Assigned to Arm(s): Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1, Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2 | Intervention Type: BIOLOGICAL; Name: Fluarix; Assigned to Arm(s): Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1, Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1, Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2
C: Arm Label: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine; Type: EXPERIMENTAL; Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: D46/NS2/N/ΔM2-2-HindIII; Assigned to Arm(s): RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1: Ad26.RSV.preF; Type: EXPERIMENTAL; Interventions: Biological: Ad26.RSV.preF | Arm Label: Group 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Ad26.RSV.preF; Assigned to Arm(s): Group 1: Ad26.RSV.preF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Placebo

Answer: B